Opendata, web and dolomites

ProMeta SIGNED

Non-histone protein acetylation targets of KAT2A in AML

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ProMeta project word cloud

Explore the words cloud of the ProMeta project. It provides you a very rough idea of what is the project "ProMeta" about.

maturation    regulates    mutation    acetylation    first    bone    free    received    considering    ing    transplantation    acute    transcriptional    hat    reprogramming    developmental    identity    pathogenesis    implicated    mainstay    blasts    found    themes    function    alpha    acetyl    epigenetic    pkc412    yeast    therapy    protein    kat2a    extends    30    residues    investigation    survival    proliferator    patients    administration    stages    break    remained    aml    cancer    cell    receptor    aml1    clonal    expansion    fate    driving    crucially    attributable    supportive    explore    decades    modifications    hijacked    oncogenic    rare    essentially    marrow    food    gcn5    heterogeneous    leukaemia    gamma    care    evi1    biology    transferase    deranged    dysregulation    designation    fda    signalling    unchanged    pivotal    small    catalyse    paves    peroxisome    myeloid    mutated    activated    drug    fusion    modifiers    prognosis    coactivator    acetylates    interests    acetyltransferase    diseases    maintained    proteins    dismal    post       flt3    complexes    itd    disease    chains    translational    mds1    accompanying    histone   

Project "ProMeta" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

The importance of an insight into how cell fate is established and maintained, extends far beyond the interests of developmental biology. It is pivotal to our understanding of how these processes can be hijacked and deranged in diseases such as cancer, or of the factors involved in reprogramming cell identity and function. Acute Myeloid Leukaemia (AML) has a dismal prognosis with less than 30% 5-year survival. Mainstay therapy has remained essentially unchanged for the past three decades, with all small advances in disease-free survival attributable to transplantation and improved supportive care. Only recently PKC412 has received Food and Drug Administration (FDA)’s break through therapy designation for the FLT3-ITD AML. This paves the way for investigation considering that FLT3-ITD as a driving oncogenic mutation has been found in ~30% of the AML patients. The pathogenesis of AML is heterogeneous, but there are common themes of epigenetic, transcriptional and signalling dysregulation that contribute to the resulting clonal expansion of blasts at different stages of maturation, and accompanying bone marrow failure. A significant number of the most commonly mutated targets in AML are histone modifiers, i.e. proteins or complexes that catalyse post-translational modifications in specific residues of the histone side chains. A less studied acetyltransferase, but crucially implicated in AML is KAT2A, the first histone acetyl-transferase (HAT) identified in yeast.GCN5 also acetylates the AML1/MDS1/EVI1 fusion protein in rare cases of AML.KAT2A regulates the activity of Peroxisome Proliferator- Activated Receptor Gamma-Coactivator-1α and B through protein acetylation. The goal of this proposal is to explore the role of KAT2A in Acute Myeloid Leukaemia (AML) through investigation of its non-histone protein acetylation activity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROMETA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROMETA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GenEl (2020)

General readout electronics for cross-sectoral application in European research infrastructure

Read More  

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More  

NeuroSens (2019)

Neuromodulation of Sensory Processing

Read More